UMeWorld Limited Announces Groundbreaking Study Published in the Journal of Lipid Research, Highlighting the Benefits of Low Triglyceride DAGola Cooking Oil for Athletes
18 févr. 2025 08h00 HE
|
UMeWorld Limited
UMeWorld announces groundbreaking study on DAGola oil, showing benefits in reducing uric acid and triglycerides for athletes, supporting long-term health.
Fractyl Health Reports Third Quarter 2024 Financial Results and Provides Business Updates
12 nov. 2024 16h05 HE
|
Fractyl Health, Inc.
REMAIN-1 weight maintenance pivotal study enrollment progressing rapidly; mid-point data analysis expected in Q2 2025
Cookie Diet announces the launch of new Four-Week Program
14 oct. 2024 10h20 HE
|
Cookie Diet
America’s most convenient diet revealed: These famous weight-loss cookies make it easy to shred kilos AND there’s a money-back guarantee.
Cookie Diet announces the launch of new Four-Week Program
13 oct. 2024 19h20 HE
|
Cookie Diet
Australia’s most convenient diet revealed: These famous weight-loss cookies make it easy to shred kilos AND there’s a money-back guarantee.
Fractyl Health to Present at Chardan’s 8th Annual Genetic Medicines Conference
24 sept. 2024 07h00 HE
|
Fractyl Health, Inc.
Fractyl Health to Present at Chardan’s 8th Annual Genetic Medicines Conference
Fractyl Health to Participate in Upcoming September Investor Conferences
03 sept. 2024 07h00 HE
|
Fractyl Health, Inc.
Fractyl Health to Participate in Upcoming September Investor Conferences
Fractyl Health Reports Second Quarter 2024 Financial Results and Provides Business Updates
14 août 2024 16h05 HE
|
Fractyl Health, Inc.
Fractyl Health Reports Second Quarter 2024 Financial Results and Provides Business Updates
Clearmind Medicine: New Scientific Publication Shows MEAI's Potential as a Novel Weight Loss Drug
06 août 2024 08h57 HE
|
Clearmind Medicine Inc.
Vancouver, Canada, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and...
SciSparc’s Collaboration with Clearmind Medicine Continues to Bear Fruit With New Scientific Article Showing MEAI Potential as a Novel Weight Loss Drug
06 août 2024 08h57 HE
|
SciSparc Ltd
SciSparc has been collaborating with Clearmind Medicine to create effective treatments for obesity and metabolic syndrome by combining SciSparc’s Palmitoylethanolamide (PEA) with Clearmind’s MEAI ...
Fractyl Health Receives FDA Breakthrough Device Designation for Revita in Weight Maintenance for People with Obesity Who Discontinue GLP-1 Based Drugs
30 juil. 2024 07h00 HE
|
Fractyl Health, Inc.
Fractyl Health Receives FDA Breakthrough Device Designation for Revita in Weight Maintenance for People with Obesity Who Discontinue GLP-1 Based Drugs